We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+33.7%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.99B
AUM Growth
-$172M
Cap. Flow
-$171M
Cap. Flow %
-8.58%
Top 10 Hldgs %
59.05%
Holding
53
New
18
Increased
6
Reduced
17
Closed
6

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$68.6M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$55M
3
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$39.2M
4
AGMB
AgomAb Therapeutics NV
AGMB
+$34.9M
5
MAZE
Maze Therapeutics
MAZE
+$33.1M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$69.8M
2
ENGN icon
enGene Therapeutics
ENGN
+$36.1M
3
BBIO icon
BridgeBio Pharma
BBIO
+$25.4M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$20M
5
GHRS icon
GH Research
GHRS
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Financials 0.66%

No holdings matched the selected filter criteria.

1 2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Cormorant Asset Management held 53 positions worth $1.99B, down 7.9% from $2.16B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management withdrew a net $171M in Q1 2026, closing 6 positions and reducing 17 holdings. Its most notable exit was enGene Therapeutics, an estimated $36.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 82% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Erasca worth $93.8M.

  • Cormorant Asset Management's largest Q1 2026 buy was Erasca: 5,800,000 shares worth $93.8M.
  • Cormorant Asset Management added most to Olema Pharmaceuticals in Q1 2026, an estimated $25.6M increase.
  • Cormorant Asset Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $69.8M.
  • Cormorant Asset Management fully exited enGene Therapeutics in Q1 2026, selling an estimated $36.1M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.99B portfolio in Q1 2026.
  • Cormorant Asset Management opened 18 new positions and closed 6 in Q1 2026.
  • Cormorant Asset Management's portfolio value fell 7.9% quarter-over-quarter to $1.99B.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.